This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

US approves first vaccine against chikungunya virus

chikungunya virus
Credit: AI-generated image (disclaimer)

US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health threat."

The vaccine, developed by Europe's Valneva which will be marketed under the name Ixchiq, was approved for people 18 and over who are at increased risk of exposure, the FDA said.

Ixchiq's green-light by the US drug regulator is expected to speed the vaccine's rollout in countries where the virus is most prevalent.

Chikungunya, which causes fever and severe joint pain, is generally seen in tropical and subtropical regions of Africa, southeast Asia and parts of the Americas.

"However, virus has spread to new geographical areas causing a rise in global prevalence of the disease," the FDA said, reporting more than five million cases in the past 15 years.

"Infection with chikungunya virus can lead to and prolonged health problems, particularly for and individuals with underlying medical conditions," senior FDA official Peter Marks said in a statement.

"Today's approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options."

Symptoms can sometimes last for months or even years, but the virus is rarely fatal. There is currently no specific drug to treat chikungunya, aside from common medications for pain and fever relief.

In the absence of preventative treatment, until now the only way to protect against infection was to avoid getting bitten.

The vaccine is injected in one dose and contains a live, weakened version of the chikungunya virus, as is standard with other vaccines.

Two were carried out in North America on 3,500 people. Headache, fatigue, muscle and joint pain, fever and nausea were commonly reported side effects.

Serious reactions were reported in 1.6 percent of Ixchiq recipients in the trials, with two requiring hospitalization.

Some vaccine recipients had chikungunya-like adverse reactions that lasted for 30 days or more.

Chikungunya can be passed from a pregnant person to their unborn child, and the virus can be fatal to newborns.

The FDA in its statement noted it was not known whether the vaccine virus can be transmitted from mother to a baby in utero, nor if the can cause adverse effects in newborns.

Since chikungunya was first identified in Tanzania in 1952, it has been recorded in more than 110 countries, according to the World Health Organization.

Public health experts have expressed concerns that chikungunya could be a potential future pandemic threat as pushes the mosquitoes that spread it into new regions.

An application for authorization has also been filed by Valneva with the European Medicines Agency (EMA).

© 2023 AFP

Citation: US approves first vaccine against chikungunya virus (2023, November 10) retrieved 27 February 2024 from https://medicalxpress.com/news/2023-11-vaccine-chikungunya-virus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Key muscle protein may unlock the mystery of chronic mosquito-borne viral illness

13 shares

Feedback to editors